via University of California San Diego
Nanoengineers at the University of California San Diego have developed COVID-19 vaccine candidates that can take the heat. Their key ingredients? Viruses from plants or bacteria.
The new fridge-free COVID-19 vaccines are still in the early stage of development. In mice, the vaccine candidates triggered high production of neutralizing antibodies against SARS-CoV-2, the virus that causes COVID-19. If they prove to be safe and effective in people, the vaccines could be a big game changer for global distribution efforts, including those in rural areas or resource-poor communities.
“What’s exciting about our vaccine technology is that is thermally stable, so it could easily reach places where setting up ultra-low temperature freezers, or having trucks drive around with these freezers, is not going to be possible,” said Nicole Steinmetz, a professor of nanoengineering and the director of the Center for Nano-ImmunoEngineering at the UC San Diego Jacobs School of Engineering.
The vaccines are detailed in a paper published Sept. 7 in the Journal of the American Chemical Society.
The researchers created two COVID-19 vaccine candidates. One is made from a plant virus, called cowpea mosaic virus. The other is made from a bacterial virus, or bacteriophage, called Q beta.
Both vaccines were made using similar recipes. The researchers used cowpea plants and E. coli bacteria to grow millions of copies of the plant virus and bacteriophage, respectively, in the form of ball-shaped nanoparticles. The researchers harvested these nanoparticles and then attached a small piece of the SARS-CoV-2 spike protein to the surface. The finished products look like an infectious virus so the immune system can recognize them, but they are not infectious in animals and humans. The small piece of the spike protein attached to the surface is what stimulates the body to generate an immune response against the coronavirus.
The researchers note several advantages of using plant viruses and bacteriophages to make their vaccines. For one, they can be easy and inexpensive to produce at large scales. “Growing plants is relatively easy and involves infrastructure that’s not too sophisticated,” said Steinmetz. “And fermentation using bacteria is already an established process in the biopharmaceutical industry.”
Another big advantage is that the plant virus and bacteriophage nanoparticles are extremely stable at high temperatures. As a result, the vaccines can be stored and shipped without needing to be kept cold. They also can be put through fabrication processes that use heat. The team is using such processes to package their vaccines into polymer implants and microneedle patches. These processes involve mixing the vaccine candidates with polymers and melting them together in an oven at temperatures close to 100 degrees Celsius. Being able to directly mix the plant virus and bacteriophage nanoparticles with the polymers from the start makes it easy and straightforward to create vaccine implants and patches.
The goal is to give people more options for getting a COVID-19 vaccine and making it more accessible. The implants, which are injected underneath the skin and slowly release vaccine over the course of a month, would only need to be administered once. And the microneedle patches, which can be worn on the arm without pain or discomfort, would allow people to self-administer the vaccine.
“Imagine if vaccine patches could be sent to the mailboxes of our most vulnerable people, rather than having them leave their homes and risk exposure,” said Jon Pokorski, a professor of nanoengineering at the UC San Diego Jacobs School of Engineering, whose team developed the technology to make the implants and microneedle patches.
“If clinics could offer a one-dose implant to those who would have a really hard time making it out for their second shot, that would offer protection for more of the population and we could have a better chance at stemming transmission,” added Pokorski, who is also a founding faculty member of the university’s Institute for Materials Discovery and Design.
In tests, the team’s COVID-19 vaccine candidates were administered to mice either via implants, microneedle patches, or as a series of two shots. All three methods produced high levels of neutralizing antibodies in the blood against SARS-CoV-2.
Potential Pan-Coronavirus Vaccine
These same antibodies also neutralized against the SARS virus, the researchers found.
It all comes down to the piece of the coronavirus spike protein that is attached to the surface of the nanoparticles. One of these pieces that Steinmetz’s team chose, called an epitope, is almost identical between SARS-CoV-2 and the original SARS virus.
“The fact that neutralization is so profound with an epitope that’s so well conserved among another deadly coronavirus is remarkable,” said co-author Matthew Shin, a nanoengineering Ph.D. student in Steinmetz’s lab. “This gives us hope for a potential pan-coronavirus vaccine that could offer protection against future pandemics.”
Another advantage of this particular epitope is that it is not affected by any of the SARS-CoV-2 mutations that have so far been reported. That’s because this epitope comes from a region of the spike protein that does not directly bind to cells. This is different from the epitopes in the currently administered COVID-19 vaccines, which come from the spike protein’s binding region. This is a region where a lot of the mutations have occurred. And some of these mutations have made the virus more contagious.
Epitopes from a nonbinding region are less likely to undergo these mutations, explained Oscar Ortega-Rivera, a postdoctoral researcher in Steinmetz’s lab and the study’s first author. “Based on our sequence analyses, the epitope that we chose is highly conserved amongst the SARS-CoV-2 variants.”
This means that the new COVID-19 vaccines could potentially be effective against the variants of concern, said Ortega-Rivera, and tests are currently underway to see what effect they have against the Delta variant, for example.
Plug and Play Vaccine
Another thing that gets Steinmetz really excited about this vaccine technology is the versatility it offers to make new vaccines. “Even if this technology does not make an impact for COVID-19, it can be quickly adapted for the next threat, the next virus X,” said Steinmetz.
Making these vaccines, she says, is “plug and play:” grow plant virus or bacteriophage nanoparticles from plants or bacteria, respectively, then attach a piece of the target virus, pathogen, or biomarker to the surface.
“We use the same nanoparticles, the same polymers, the same equipment, and the same chemistry to put everything together. The only variable really is the antigen that we stick to the surface,” said Steinmetz.
The resulting vaccines do not need to be kept cold. They can be packaged into implants or microneedle patches. Or, they can be directly administered in the traditional way via shots.
Steinmetz and Pokorski’s labs have used this recipe in previous studies to make vaccine candidates for diseases like HPV and cholesterol. And now they’ve shown that it works for making COVID-19 vaccine candidates as well.
Next Steps
The vaccines still have a long way to go before they make it into clinical trials. Moving forward, the team will test if the vaccines protect against infection from COVID-19, as well as its variants and other deadly coronaviruses, in vivo.
Original Article: These Fridge-Free COVID-19 Vaccines Are Grown in Plants and Bacteria
More from: University of California San Diego | Jacobs School of Engineering | Utah State University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
COVID-19 vaccine
- How a simulation is informing COVID-19 vaccine policy after our 'return to normal'on May 20, 2024 at 12:05 pm
Our results suggest that populations with low vaccination coverage and high past infection rates should still consider vaccination if public health measures are not enforced or social mixing is not ...
- With new variants, do experts predict a summer COVID-19 surge?on May 20, 2024 at 11:38 am
As variants overtake earlier versions of the coronavirus, experts say the existing low number of cases could surge ...
- Moderna and Novavax Hope for Early Launch of This Year’s Covid-19 Shots, Despite FDA Delayon May 20, 2024 at 11:31 am
After disappointing sales for their Covid vaccines last year, drugmakers are hoping for an August rollout of the updated shot.
- Will New Zealand end COVID-19 vaccine mandates in workplaces?on May 20, 2024 at 10:25 am
New Zealand First secured the pledge when it joined the coalition government last year. In the coalition agreement between First and the National Party, it stated there that it will "uphold the ...
- askST: Can current vaccines protect against new Covid-19 variants?on May 20, 2024 at 7:37 am
The key question is when the new vaccines to protect against the new variants will be available. Read more at straitstimes.com.
Go deeper with Google Headlines on:
COVID-19 vaccine
[google_news title=”” keyword=”COVID-19 vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Pan-Coronavirus Vaccine
- African anti-rights groups and anti-vaxxers unite in global conspiracy against WHOon May 20, 2024 at 12:49 pm
Right-wing African members of parliament, including some of the continent’s most vociferous anti-abortion, anti-LGBTQI lawmakers, united with anti-vax conspiracy theorists for the first time at a ...
- COVID and SARS Newson May 15, 2024 at 5:00 pm
The research promises to help scientists design and improve 'pan-coronavirus' vaccines that elicit broad, cross-protective ... Apr. 3, 2024 — To better understand COVID-19's spread during the ...
- VBI Vaccines Reports First Quarter 2024 Financial Resultson May 15, 2024 at 1:53 pm
s multivalent pan-coronavirus vaccine candidate – initial data from which were reported in September 2023 Foreign exchange loss for the first quarter of 2024 was $4.3 million as compared to $6.8 ...
- Research aims to develop vaccine against future COVID viruseson May 6, 2024 at 7:48 am
Scientists are busy working on a vaccine that might fight strains of the COVID virus SARS-CoV-2 that haven't even emerged yet.
- Advanced Immunotechnologies and Vaccine Formulationson December 8, 2023 at 12:38 pm
The Laboratory for Advanced Immunotechnologies and Formulation aims to explore and advance vaccine technologies to develop novel and improved vaccine solutions. "Amastigote" usually refers to the ...
Go deeper with Google Headlines on:
Pan-Coronavirus Vaccine
[google_news title=”” keyword=”Pan-Coronavirus Vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]